NASDAQ:FENC - Fennec Pharmaceuticals Stock Price, Forecast & News

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.11. View Fennec Pharmaceuticals' Earnings History.

Fennec Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Fennec Pharmaceuticals.

2 brokers have issued 12-month price targets for Fennec Pharmaceuticals' shares. Their forecasts range from $16.00 to $17.00. On average, they anticipate Fennec Pharmaceuticals' stock price to reach $16.50 in the next year. This suggests a possible upside of 164.0% from the stock's current price. View Analyst Price Targets for Fennec Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fennec Pharmaceuticals.

Headlines about FENC stock have trended negative on Wednesday, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fennec Pharmaceuticals earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Fennec Pharmaceuticals.

Fennec Pharmaceuticals saw a increase in short interest in the month of January. As of January 15th, there was short interest totalling 469,400 shares, an increase of 10.4% from the December 31st total of 425,000 shares. Based on an average trading volume of 33,000 shares, the short-interest ratio is currently 14.2 days. Approximately 2.9% of the shares of the stock are short sold. View Fennec Pharmaceuticals' Current Options Chain.

Some companies that are related to Fennec Pharmaceuticals include Translate Bio (TBIO), Verona Pharma (TARA), Aptose Biosciences (APTO), Voyager Therapeutics (VYGR), Cabaletta Bio (CABA), BioCryst Pharmaceuticals (BCRX), Adaptimmune Therapeutics (ADAP), Autolus Therapeutics (AUTL), Tcr2 Therapeutics (TCRR), PDL BioPharma (PDLI), Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), Compugen (CGEN), Cellular Biomedicine Group (CBMG) and Eiger Biopharmaceuticals (EIGR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Iovance Biotherapeutics (IOVA), Amarin (AMRN), Fate Therapeutics (FATE), Karyopharm Therapeutics (KPTI), Allena Pharmaceuticals (ALNA), Coherus Biosciences (CHRS), Denali Therapeutics (DNLI), Pieris Pharmaceuticals (PIRS), Aptose Biosciences (APTO) and Cidara Therapeutics (CDTX).

Fennec Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Hartford Financial Management Inc. (0.18%) and Wedbush Securities Inc. (0.12%). View Institutional Ownership Trends for Fennec Pharmaceuticals.

FENC stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc. and Hartford Financial Management Inc.. View Insider Buying and Selling for Fennec Pharmaceuticals.

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FENC stock can currently be purchased for approximately $6.25.

Fennec Pharmaceuticals has a market capitalization of $124.38 million. The company earns $-9,890,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. View Additional Information About Fennec Pharmaceuticals.

The official website for Fennec Pharmaceuticals is http://www.fennecpharma.com/.

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.